Balversa 5 mg – DIN 02493233
Balversa is Erdafitinib 5 mg (tablet), sold in Canada. It is used for transitional cell carcinoma. It is supplied by Janssen Inc. We don't have a photo or description of what this pill looks like yet, so check the name and code on the box or bottle, and ask a pharmacist before taking it. Its official Health Canada listing links to the product monograph, which describes the tablets.
Sold in Canada
Erdafitinib 5 mg
- Brand
- Balversa
- Strength
- 5 mg
- Used for
- Transitional cell carcinoma
- Form
- Tablet
- Manufacturer
- Janssen Inc
- Drug class
- Cancer medicine (kinase inhibitor)
- Sold in
- Canada
- DIN
- 02493233
Source: Health Canada's Drug Product Database. Last checked .
Report a mistake
What is Erdafitinib used for?
Erdafitinib is used for transitional cell carcinoma.
- Medicine type
- Cancer medicine (kinase inhibitor)
Official uses from the US prescribing label
BALVERSA is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy.
Select patients for therapy based on an FDA-approved companion diagnostic for BALVERSA.
Limitations of Use
BALVERSA is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.
From the FDA-approved label on DailyMed (published Nov 17, 2025).
Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.
Is this your medicine? Check the box
- The box or bottle shows DIN 02493233.
- It names Balversa, Erdafitinib 5 mg.
- A loose pill is a different matter: without a description of its markings, a pharmacist has to confirm what it is.
Sold in Canada as Balversa by Janssen Inc.
In Canada: prescription only.
Ingredients
Active: Erdafitinib
Other Erdafitinib pills
- 3 EF Erdafitinib 3 mg Yellow, round, 8 mm Used for transitional cell carcinoma
- 3 EF Erdafitinib 3 mg Yellow, round Used for transitional cell carcinoma
- 4 EF Erdafitinib 4 mg Orange, round, 8 mm Used for transitional cell carcinoma
- 4 EF Erdafitinib 4 mg Orange, round Used for transitional cell carcinoma
- 5 EF Erdafitinib 5 mg Brown, round, 9 mm Used for transitional cell carcinoma